Background Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy
protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers. …

Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had acute …

Background— Among patients with implantable pacemakers and defibrillators, subclinical
atrial fibrillation (SCAF) is associated with an increased risk of stroke; however, there is limited …

Background Surgical occlusion of the left atrial appendage has been hypothesized to
prevent ischemic stroke in patients with atrial fibrillation, but this has not been proved. The …

Background In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous
coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death …

Background— The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY)
trial showed that dabigatran etexilate 150 mg BID was superior and dabigatran etexilate 110 …

Background— Atrial fibrillation (AF) is the most common sustained arrhythmia; however,
little is known about patients in a primary care setting from high-, middle-, and low-income …

Background Atrial fibrillation is an important cause of morbidity and mortality worldwide, but
scant data are available for long-term outcomes in individuals outside North America or …

Background The precise age distribution and calculated stroke risk of screen-detected atrial
fibrillation (AF) is not known. Therefore, it is not possible to determine the number needed to …

Objective The prevalence of atrial fibrillation (AF) and the risk of stroke and bleeding vary
according to age. To estimate effects of dabigatran, compared with warfarin, on stroke, …